348 related articles for article (PubMed ID: 15520166)
1. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
[TBL] [Abstract][Full Text] [Related]
2. Dendrimer- and polymeric nanoparticle-aptamer bioconjugates as nonviral delivery systems: a new approach in medicine.
Mignani S; Shi X; Ceña V; Majoral JP
Drug Discov Today; 2020 Jun; 25(6):1065-1073. PubMed ID: 32283193
[TBL] [Abstract][Full Text] [Related]
3. Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells.
Ghorbani R; Gharbavi M; Sharafi A; Rismani E; Rezaeejam H; Mortazavi Y; Johari B
Oncol Res; 2023; 32(1):101-125. PubMed ID: 38188680
[TBL] [Abstract][Full Text] [Related]
4. RNA aptamer-mediated gene therapy of prostate cancer: lessons from the past and future directions.
Arese M; Mahmoudian M; Bussolino F
Expert Opin Drug Deliv; 2023; 20(11):1609-1621. PubMed ID: 38058168
[TBL] [Abstract][Full Text] [Related]
5. Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer.
Subjakova V; Oravczova V; Hianik T
Polymers (Basel); 2021 Jan; 13(3):. PubMed ID: 33494545
[TBL] [Abstract][Full Text] [Related]
6. Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells.
Luks VL; Mandl H; DiRito J; Barone C; Freedman-Weiss MR; Ricciardi AS; Tietjen GG; Egan ME; Saltzman WM; Stitelman DH
PLoS One; 2022; 17(4):e0266218. PubMed ID: 35385514
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the characteristics of D4 and R4 aptamers for their future use in prostate cancer clinical practice.
Campos-Fernández E; Alqualo NO; Vaz ER; Rodrigues CM; Alonso-Goulart V
Biophys Chem; 2024 Aug; 311():107259. PubMed ID: 38763045
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
[TBL] [Abstract][Full Text] [Related]
9. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-aptamer bioconjugates for cancer targeting.
Farokhzad OC; Karp JM; Langer R
Expert Opin Drug Deliv; 2006 May; 3(3):311-24. PubMed ID: 16640493
[TBL] [Abstract][Full Text] [Related]
11. Nanocarriers as an emerging platform for cancer therapy.
Peer D; Karp JM; Hong S; Farokhzad OC; Margalit R; Langer R
Nat Nanotechnol; 2007 Dec; 2(12):751-60. PubMed ID: 18654426
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
13. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform.
Bagalkot V; Farokhzad OC; Langer R; Jon S
Angew Chem Int Ed Engl; 2006 Dec; 45(48):8149-52. PubMed ID: 17099918
[No Abstract] [Full Text] [Related]
14. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
Bagalkot V; Zhang L; Levy-Nissenbaum E; Jon S; Kantoff PW; Langer R; Farokhzad OC
Nano Lett; 2007 Oct; 7(10):3065-70. PubMed ID: 17854227
[TBL] [Abstract][Full Text] [Related]
15. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.
Wang AZ; Bagalkot V; Vasilliou CC; Gu F; Alexis F; Zhang L; Shaikh M; Yuet K; Cima MJ; Langer R; Kantoff PW; Bander NH; Jon S; Farokhzad OC
ChemMedChem; 2008 Sep; 3(9):1311-5. PubMed ID: 18613203
[No Abstract] [Full Text] [Related]
16. Impact of nanotechnology on drug delivery.
Farokhzad OC; Langer R
ACS Nano; 2009 Jan; 3(1):16-20. PubMed ID: 19206243
[TBL] [Abstract][Full Text] [Related]
17. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.
Zhang L; Chan JM; Gu FX; Rhee JW; Wang AZ; Radovic-Moreno AF; Alexis F; Langer R; Farokhzad OC
ACS Nano; 2008 Aug; 2(8):1696-702. PubMed ID: 19206374
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates.
Zhang L; Radovic-Moreno AF; Alexis F; Gu FX; Basto PA; Bagalkot V; Jon S; Langer RS; Farokhzad OC
ChemMedChem; 2007 Sep; 2(9):1268-71. PubMed ID: 17600796
[No Abstract] [Full Text] [Related]
19. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology and aptamers: applications in drug delivery.
Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
